From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-Label, Multicentre ZUMA-3 Study

The phase 2 results of the ZUMA-3 study, which evaluated brexucabtagene autoleucel (KTE-X19), an anti-CD19 CAR T-cell therapy, in adults with relapsed or refractory B-cell acute lymphoblastic leukemia, showed a high rate of complete remission or complete remission with incomplete hematological recovery, with the median overall survival not reached in responding patients and a manageable safety profile.

The Lancet
Advertisement
News & Literature Highlights
Advertisement
Advertisement